Medifast, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023; filed August 7, 2023. Unaudited results. Medifast sells health and wellness products primarily through its OPTAVIA Coach-guided model.
Financial performance
| Metric | Q2 2023 | Q2 2022 | First six months 2023 | First six months 2022 |
|---|---|---|---|---|
| Revenue | $296.2 million | $453.3 million | $645.2 million | $870.9 million |
| Gross profit / margin | $210.7 million / 71.1% | $321.7 million / 71.0% | $457.1 million / 70.9% | $624.0 million / 71.6% |
| Operating income / margin | $38.7 million / 13.1% | $49.0 million / 10.8% | $92.2 million / 14.3% | $104.1 million / 11.9% |
| Net income | $30.3 million | $39.1 million | $70.2 million | $80.9 million |
| Diluted EPS | $2.77 | $3.42 | $6.43 | $7.01 |
| Operating cash flow | Not separately stated | Not separately stated | $107.2 million | $87.4 million |
Revenue and margins: Q2 revenue fell 34.7% year over year; first-half revenue fell 25.9%. Management attributed the declines mainly to fewer active earning Coaches and lower productivity per Coach. Active earning Coaches declined to 53,100 from 68,000 year over year. Average revenue per active earning Coach was $5,578 in Q2 versus $6,667, and $5,771 for the first half versus $6,603. Q2 gross margin edged up 0.1 percentage point, while first-half gross margin declined 0.7 percentage point. Lower sales volumes, fixed-cost deleveraging and inflation in ingredients, shipping and labor affected results. SG&A declined faster than revenue, helping operating margins improve in both periods.
Cash, liquidity and debt: Cash and cash equivalents were $147.4 million at June 30, 2023, up from $87.7 million at year-end 2022. Working capital was $113.9 million, compared with $81.9 million. First-half operating cash flow was $107.2 million; investing cash outflow was $3.9 million and financing cash outflow was $43.7 million. The operating cash flow increase reflected, among other items, lower inventory. Inventory fell to $68.9 million from $118.9 million at year-end; the obsolete-inventory reserve rose to $8.7 million from $3.8 million. The company had no borrowings under its $225 million revolving credit facility and reported compliance with covenants. The facility matures in April 2026.
Capital returns: The company declared dividends of $1.65 per share for Q2 and $3.30 per share for the first half. It paid $37.0 million in dividends and repurchased $3.6 million of stock in the first half. The Q2 dividend was payable August 8, 2023. Future dividends and repurchases are subject to Board discretion and business conditions.
Material changes and notable items
- In Q1 2023, Medifast changed customer terms so revenue is recognized upon delivery to the shipping carrier rather than customer receipt. The change increased Q1 revenue by approximately $9.1 million and operating income by $2.8 million; management also described a $9.1 million first-half revenue timing impact.
- Cost reductions and optimization, lower Coach compensation and the absence of Q2 2022 charitable donations contributed to lower SG&A. A tax benefit related to charitable inventory donations was also lower, contributing to higher effective tax rates: 22.6% in Q2 versus 19.8%, and 24.0% for the first half versus 22.0%.
- Management reversed $1.4 million of first-half share-based compensation expense after determining 2022 market- and performance-based awards would not meet the lower performance threshold.
- After quarter-end, Medifast exited Hong Kong and Singapore operations effective July 1, citing changed regional economics and resource priorities. On July 27, it announced OPTAVIA ACTIVE products, with a planned September 2023 launch, to enter sports nutrition. The company also began a small pilot with telehealth providers combining its program with medically supported weight-loss options, including GLP-1 drugs.
Outlook, risks and contingencies
The filing provides no numerical revenue or earnings guidance. Management said it expects any future cash requirements to be funded through operating cash flow and financing activities and plans to invest in technology, digital capabilities and product expansion. It cited continued pressure on customer acquisition, inflation and labor-market conditions, consumer spending uncertainty, supply-chain costs and broader macroeconomic volatility. Management noted that the war in Ukraine had not materially affected the business to date. Ordinary-course litigation was not expected to materially affect results, financial position or liquidity, although outcomes cannot be predicted. The filing reported no material changes to risk factors from the 2022 Form 10-K. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether Coach counts and revenue productivity stabilize, and whether customer-acquisition pressure eases.
- How much the Q1 revenue-recognition timing change affected period comparisons and whether it has continuing effects.
- Whether inventory levels and the higher obsolete-inventory reserve reflect demand alignment or additional potential write-offs.
- Execution, costs and customer response for the Hong Kong and Singapore exit, OPTAVIA ACTIVE launch and telehealth/GLP-1 pilot.
- Future cash generation and the sustainability of dividends and repurchases as earnings decline.
- Compliance with credit-facility covenants and any material developments in litigation or macroeconomic risks.